A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients with Generalized Myasthenia Gravis IND 140,115 STUDY NUMBER: ALXN1210-MG-306

  • STATUS
    Not Recruiting
Updated on 18 June 2021
corticosteroids
tacrolimus
mycophenolate mofetil
cyclophosphamide
cyclosporine
methotrexate
cholinesterase inhibitors
azathioprine
serologic test
myasthenia gravis
generalized myasthenia gravis
repetitive nerve stimulation
acetylcholinesterase inhibitors
edrophonium chloride
edrophonium chloride test
anticholinesterase agents

Summary

Primary
To assess the efficacy of ravulizumab compared with placebo in the treatment of gMG based on the improvement in the Myasthenia Gravis-Activities of Daily Living (MG-ADL) profile.
Secondary
To assess the efficacy of ravulizumab compared with placebo in the treatment of gMG based on the improvement in the Quantitative Myasthenia Gravis (QMG) total score.
 

Description

There are no medical benefits that can be guaranteed to the patient for the patient’s taking part in this research study. The patient’s willingness to take part, however, may help doctors better understand and/or treat others who have the patient’s condition. Information gained from this study may benefit others. No guarantees have been made to the patient as to the results of this research study.

Details
Condition Myasthenia Gravis generalised
Clinical Study IdentifierTX220311
Last Modified on18 June 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note